News » Money
Apr 24, 4:42 PM EDT

D.R. Horton, Apple, Zimmer, Facebook and Caterpillar are big market movers

Business Video

Buy AP Photo Reprints
Greece's Debt Threatens to Spread
State budget
gaps map
Auto industry problems trickle down, punish Tennessee county
Women give old Derby hats a makeover in tough economy
S.C. town deals with highest unemployment in South
How mortgages were bundled and sold as securities
Tracking the $700 billion financial bailout
Tracking the year's job losses
State-by-state foreclosures since 2007
Credit crisis explained
Presidents and their economic legacies
Lexicon of the financial crisis
Americans' addiction to debt
Are Stocks Bouncing Back?

NEW YORK (AP) -- Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:


Zimmer Holdings Inc., up $10.52 to $101.97

The medical device maker snaps up Biomet for more than $13 billion, an acquisition that will be an immediate boost to its earnings.

Caterpillar Inc., up $1.90 to $105.28

The construction equipment maker raised its 2014 earnings forecast and quarterly earnings jumped 5 percent even with mining sales slow.

United Parcel Service Inc., down 60 cents to $98.64

Terrible weather hampered the shipping giant and it fell short of Wall Street expectations for the first quarter.

D.R. Horton Inc., up $1.78 to $23.13

Profit at the nation's largest homebuilder jumped 18 percent in the first quarter as it sold more homes and benefited from rising prices.


Apple Inc., up $43.02 to $567.77

A seven-for-one stock split and a fat dividend payout upstaged a strong quarter from the tech giant, which topped expectations.

Facebook Inc., down 49 cents to $60.87

Spiking ad revenue at the social network fueled a tripling of earnings and sharply higher revenue during the first quarter.

Zynga, Inc., down 7 cents to $4.35

Founder Mark Pincus is stepping down as chief product officer, a show of confidence in Don Mattrick, who replaced him as CEO.

Celgene Corp., down $3.57 to $141.25

First-quarter revenue soared 18 percent as the drugmaker rode strong sales of its cornerstone blood-cancer treatment, Revlimid.

© 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy and Terms of Use.